Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform [Yahoo! Finance]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: Yahoo! Finance
for underserved medical needs, today announced the filing of two U.S. provisional patent applications that significantly expand the Company's intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies. The first provisional patent application, titled covering the topical treatment of radiation-induced skin toxicity in oncology patients. The second provisional patent application, titled addressing dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors. Together, these dual filings secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents. As cancer treatments become more effective and patients remain on therapy longer, managing treatment-limiting skin toxicities
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site ActivationPR Newswire
- Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP PlatformPR Newswire
- Hoth Therapeutics (NASDAQ:HOTH) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Hoth Therapeutics (NASDAQ:HOTH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic ProgramPR Newswire
HOTH
Sec Filings
- 1/16/26 - Form 8-K
- 12/5/25 - Form EFFECT
- 11/17/25 - Form S-3
- HOTH's page on the SEC website